Evaluating conventional and novel drug delivery systems: A comparative study and their applications in treatment of lung cancer in twin cities of Pakistan

Abstract

In Pakistan's twin cities of Rawalpindi and Islamabad, lung cancer, a prevalent and deadly malignancy globally, presents significant treatment challenges. The use of conventional therapies such as radiation and chemotherapy, despite their widespread application, is hindered by their limitations, including non-targeted systemic toxicity, which significantly reduces their overall effectiveness. Novel drug delivery systems, particularly those utilizing nanotechnology, present notable advancements in cancer cell targeting, reduced side effects, and improved patient outcomes. This study assesses the superiority in effectiveness, safety, and cost-effectiveness of Conventional and Novel Drug Delivery System for lung cancer treatment in the Twin Cities of Pakistan. 54.1% of respondents consider Novel Drug Delivery System to have a better balance between safety and efficacy compared to conventional therapies. 58.1% of respondents cited high costs, 70.3% cited limited expertise, and 47.3% cited inadequate healthcare infrastructure as hindrances to wider adoption. 70.3% of respondents emphasized the need for government support in implementing Novel Drug Delivery System technologies. To significantly improve lung cancer treatment outcomes and make cancer care more accessible for patients in the twin cities of Pakistan, it's crucial to implement location-specific approaches, raise awareness, and invest in infrastructure.